These findings corroborate those of Sun et al. 38, which also found that high IGF2BP3 expression correlates with more aggressive tumor features and poorer outcomes, particularly in liver cancer, where elevated IGF2BP3 levels were linked to shortened OS and PFS. This evidence concerns the gene IGF2BP3 and liver cancer.